These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8114853)

  • 1. Bladder preservation after treatment of invasive bladder cancer.
    Lytton B
    N Engl J Med; 1994 Mar; 330(12):867; author reply 867-8. PubMed ID: 8114853
    [No Abstract]   [Full Text] [Related]  

  • 2. [The role of preserving therapy of invasive cancer of the urinary bladder].
    Matveev BP; Sallum SD; Kamolov BSh; Figurin KM; Matveev VB; Volkova MI
    Urologiia; 2005; (6):3-6. PubMed ID: 16419470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder preservation after treatment of invasive bladder cancer.
    Berman DJ
    N Engl J Med; 1994 Mar; 330(12):867; author reply 867-8. PubMed ID: 8114852
    [No Abstract]   [Full Text] [Related]  

  • 5. Multimodality bladder preservation therapy for muscle-invasive bladder tumors.
    Fernando SA; Sandler HM
    Semin Oncol; 2007 Apr; 34(2):129-34. PubMed ID: 17382796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The management of locally recurrent invasive bladder cancer following radical cystectomy.
    Pisters LL; Westney L
    Semin Urol Oncol; 1996 May; 14(2):112-9. PubMed ID: 8734739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opportunities with combined modality therapy for selective organ preservation in muscle-invasive bladder cancer.
    Colvett KT; Althausen AF; Bassil B; Heney NM; McGovern FV; Young HH; Kaufman DS; Zietman AL; Shipley WU
    J Surg Oncol; 1996 Nov; 63(3):201-8. PubMed ID: 8944067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multimodality therapy for the treatment of muscle-invasive bladder cancer.
    Thurman SA; DeWeese TL
    Semin Urol Oncol; 2000 Nov; 18(4):313-22. PubMed ID: 11101096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatments in invasive bladder cancer].
    Bouchot O; Zerbib M
    Prog Urol; 2003 Dec; 13(6):1415-27. PubMed ID: 15000325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combined therapy for patients with invasive bladder cancer].
    Startsev VIu; Karelin MI
    Vopr Onkol; 2003; 49(2):235-8. PubMed ID: 12785212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant treatment of invasive bladder cancer.
    Semin Oncol; 1990 Oct; 17(5):515-638. PubMed ID: 2218562
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of invasive bladder cancer.
    Dinney CP
    Urology; 2006 Mar; 67(3 Suppl 1):56-9; discussion 60-1. PubMed ID: 16530078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organ-sparing treatment of bladder cancer: an innovative approach.
    Kaufman DS; Shipley WU
    Am Fam Physician; 1997 Mar; 55(4):1257-62. PubMed ID: 9092286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.
    Weiss C; Wittlinger M; Engehausen DG; Krause FS; Ott OJ; Dunst J; Sauer R; Rödel C
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1502-6. PubMed ID: 17935905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of organ-preserving therapy for invasive bladder cancer].
    Matveev BP; Figurin KM; Toktomushev AT
    Urologiia; 2002; (3):3-5. PubMed ID: 12180056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience.
    Perdonà S; Autorino R; Damiano R; De Sio M; Morrica B; Gallo L; Silvestro G; Farella A; De Placido S; Di Lorenzo G
    Cancer; 2008 Jan; 112(1):75-83. PubMed ID: 18008364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined-modality treatment and organ preservation in bladder cancer. Do molecular markers predict outcome?
    Weiss C; Rödel F; Wolf I; Papadopoulos T; Engehausen DG; Schrott KM; Sauer R; Rödel C
    Strahlenther Onkol; 2005 Apr; 181(4):213-22. PubMed ID: 15827690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternatives to cystectomy in muscle-invasive bladder cancer.
    Goel S
    J Clin Oncol; 2003 Aug; 21(15):3003; author reply 3003-4. PubMed ID: 12885826
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of high-risk, non-muscle-invasive bladder cancer.
    Lerner SP
    Nat Clin Pract Urol; 2006 Aug; 3(8):398-9. PubMed ID: 16902498
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.